OncoMatch/Clinical Trials/NCT06084299
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer
Is NCT06084299 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Autologous Tumor Infiltrating Lymphocytes for liver cancer.
Treatment: Autologous Tumor Infiltrating Lymphocytes — Single-arm, open-label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TIL) infusion followed by IL-2 after a non-myeloablative(NMA) lymphodepletion preparative regimen for the treatment of patients with advanced liver cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Disease stage
Metastatic disease required
Metastatic lesions are confirmed by PET-CT, CT, MR and/or intraoperative exploration (more than 3, at least one accessible metastasis to procure for TILs)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
absolute neutrophil count ≥ 1×10^9/L, leukocyte count ≥ 3×10^9/L, platelet count ≥ 75×10^9/L, hemoglobin ≥ 80 g/L
Kidney function
Serum creatinine ≤ 1.5× upper normal limits
Liver function
AST and ALT ≤ 2× of upper limit of normal, Serum total bilirubin ≤ 1.5× upper normal limits, Child-Push liver function score grade is A within seven days before the cell reinfusion.
Adequate normal organ and marrow function were present, including absolute neutrophil count ≥ 1×10^9/L, leukocyte count ≥ 3×10^9/L, platelet count ≥ 75×10^9/L, hemoglobin ≥ 80 g/L, AST and ALT ≤ 2× of upper limit of normal, Serum creatinine ≤ 1.5× upper normal limits, Serum total bilirubin ≤ 1.5× upper normal limits; Child-Push liver function score grade is A within seven days before the cell reinfusion.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06084299 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages